Posted by Michael Wonder on 30 Jun 2023
Formycon announces submission of the biologics license application for FYB203, an aflibercept biosimilar candidate to the US FDA
29 June 2023 - Formycon and its license partner Klinge Biopharma announce that the biologics license application for FYB203, a biosimilar candidate for Eylea (aflibercept) has been submitted to the US FDA in line with the initial schedule.
Within 60 days after submission, FDA is expected to decide on whether to accept and to further review the biologics license application.
